Venn Life Sciences is a European CRO with over 24 years’ experience in the management & resourcing of clinical trials. We have worked acrosss all phases of clinical research, with extensive experience in multiple therapeutic and device areas.

We have worked with leading pharmaceutical, biotech and medical device companies seeking to navigate the often difficult European clinical trial landscape. We have senior management teams that have worked internationally on a range of different trial sizes, who are directly involved in the preparation, management and implemention of study activities.

Over the years our high rate of repeat business highlights our commitment to give our clients a service that is over and above what is expected of a CRO. We understand the importance of fair pricing, attention to detail and consistency in terms of project teams. These qualities are what make us a leading CRO in Europe and with just under 300 trials completed, we have the capabilities to place therapeutically aligned clinical staff on all our sponsor projects.



http://vennlifesciences.com/

Acquisition of Belfast Based CRO

RNS


RNS Number : 9806U

Venn Life Sciences Holdings PLC

09 December 2013






9 December 2013

Venn Life Sciences Holdings Plc

("Venn" or the "Company")



Acquisition of Belfast based CRO



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the acquisition of Medevol Limited, a CRO business based in Northern Ireland, for a total maximum consideration of £670,000.



Venn has acquired the entire issued share capital of Medevol Limited ("Medevol") for an initial cash consideration of £70,000, to be satisfied through the Company's existing cash resources. There will be additional deferred consideration payable of up to a maximum of £600,000 over the next two years should Medevol hit certain financial targets relating to the business's annualised profit before tax. Any additional consideration will be satisfied as to one half in cash and one half in Venn shares.



The acquisition of Belfast based Medevol further strengthens Venn's UK operations following the establishment of the UK office earlier in the year. Medevol has been active in the UK clinical trials market since 2001, conducting full-service clinical trials for global pharmaceutical and biotechnology companies. Providing services across Phases II-IV, Medevol has extensive therapeutic experience throughout a broad range of indications.



For its year ended 31 March 2014, Medevol is expected to generate revenues of around £610,000 (2013: £84,000) and to contribute a profit before tax of circa £60,000 (2013: -£35,000). This year on year growth is as a result of the recent signing of a substantial new agreement with a global pharmaceutical company to supply CRO services for multiple UK based clinical trials. This contract is expected to contribute significantly to ongoing revenues for the business.



Commenting on the acquisition, Tony Richardson, CEO of Venn, said: "Medevol is the right fit for Venn as we continue to expand our business across Europe and increase our project pipeline. Venn, Medevol and the CRM business (acquired from CRM Clinical Trials GmbH as announced on 31 October 2013) have a shared global pharmaceutical client and this acquisition affords us the opportunity to develop that relationship as a key strategic account for the group going forward. The skills and talent that we are adding to our company further enhance our reputation as a mid-sized CRO that stays close to its clients, guiding them through the often complicated process of conducting trials across Europe."



Medevol Chairman, Brendan Mullan, adds: "The Medevol team was seeking to integrate seamlessly into an organisation that can offer both our clients and staff further opportunities. Venn provides us with access to a broader client base in addition to extensive experience and skills. We are delighted to be part of a dynamic and growing CRO and look forward to the new challenges and opportunities that will arise."

Update re: Aquisition of German based CRO

RNS


RNS Number : 4463X

Venn Life Sciences Holdings PLC

13 January 2014




13 January 2014

Venn Life Sciences Holdings Plc

("Venn" or the "Company")



Update re: Acquisition of German based CRO





Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, is pleased to announce that the consideration of €0.6m payable for the acquisition of the trade and certain business assets and liabilities of CRM Clinical Trials GmbH, a German based CRO (previously announced on 31 October 2103) has been satisfied by the issue of 1,962,583 Venn shares at the current share price of 25.5 pence. Application has been made for 1,962,583 ordinary shares of 1 pence each to be admitted to trading on 14 January 2014.

Update of Evocutis plc acquisition

RNS


RNS Number : 2453C

Venn Life Sciences Holdings PLC

13 March 2014







Venn Life Sciences Holdings Plc

("Venn" or the "Company")



Update on the Acquisition of the trading assets of Evocutis plc



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the following update on the acquisition of the intellectual property rights in Labskin™, SYN1113 and related equipment of Evocutis plc, for £210,000 in new ordinary shares in Venn.



Further to the announcement issued on 25 February 2014 the Company can confirm that Evocutis plc has announced that at the general meeting of its shareholders held today, all resolutions were duly passed. As a consequence the Company will, subject to the satisfaction of the remaining conditions of completion of the acquisition, acquire:



· intellectual property rights in SYN1113;

· intellectual property rights in LabSkin™; and

· certain equipment associated with the operation of SYN1113 and/or LabSkin™.

A further announcement will be made in due course.

Skin science patent grant

RNS


RNS Number : 9839J

Venn Life Sciences Holdings PLC

19 June 2014








19 June 2014

Venn Life Sciences Holdings Plc

("Venn" or the "Company")



Venn's first skin science patent grant ignites Innovenn's commercialisation stage



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that its innovation division, Innovenn, has secured its first skin science patent for its unique anti-acne complex from the European Patent Office. The Company has also commenced commercial discussions on Labskin, the breakthrough research grade human skin testing platform.



This clinically proven Blemish Control Technology, developed by dermatologists over five years of scientific research, clinical and home usage trials, uniquely delivers a natural blend of actives deeper and faster into the epidermal skin layer than other commercially available treatments. The active complex reduces bacteria, inflammation, excess oiliness and blocked pores, resulting in noticeably clearer skin in less than four hours.



This breakthrough enables a compelling scientific platform for the commercial development of a new blemish management technology brand, expected to launch later this year.



Meanwhile, commercial partnership discussions have commenced on Labskin following the establishment of new Innovenn laboratories and offices on the Innovation Campus at Sand Hutton, UK and the recruitment of a skin science management team. First revenue flows from Labskin are expected later this year.



Tony Richardson, CEO of Venn Life Sciences commented: "After five years of dermatological research, testing and consumer trials, this patent grant confirmation from the European Patent office is a substantial step forward in the commercialisation of this unique anti-acne complex. Since our acquisition of the assets of Evocutis Plc. in March of 2014, Innovenn have made tremendous progress in terms of bringing our anti-acne and living skin equivalent technology to the marketplace."

EUR2.4m contract for pan-European coronary study

RNS


RNS Number : 0180R

Venn Life Sciences Holdings PLC

08 September 2014








Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")



€2.4m contract for pan-European coronary study



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management services and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the signing of a contract worth over €2.4 million to conduct a major international study into an innovative new heart treatment.



Working alongside Professor Keith Oldroyd of the Golden Jubilee National Hospital in Scotland, the study aims to determine whether the use of Percutaneous Coronary Intervention (PCI) with a new stent with a bio-absorbable coating could be used as an effective method for treating patients with disease in the left-main coronary artery in their heart.



Valued at over €2.4 million, the study will be conducted in five European countries over a two year period with Prof Oldroyd and Prof Robert-Jan van Guens from the prestigious Erasmus University in Rotterdam, Holland, serving as the co-principal investigators. Venn has unique experience in the management of investigator initiated studies, having previously worked with investigators on various trials throughout Europe.



Speaking about the contract, Venn CEO, Tony Richardson stated: "We are delighted to be part of this important study as it is an area of the business that we have focused on expanding in recent years. Our recent expansions and service additions allow us to supply the complete envelope of services for these studies whether they are single site or multi-country site studies. We are looking forward to working with the Professor Oldroyd and Prof Robert-Jan van Guens and contributing to advancing the research in such an important area.



"This contract follows on from the mulit-country study signed up in May this year worth over €3m and demonstrates that our wider European footprint and expanded skill base allows us to target higher value studies such as these."



Discussing the trial, Professor Keith Oldroyd, one of the Principal Investigators, Consultant Cardiologist and Director of Research at the Golden Jubilee said: "The developments in PCI and stenting over the past 20 years have been absolutely incredible. The new stent we will be using in this trial has an innovative coating, which delivers a drug to prevent re-narrowing and over a period of three to four months, dissolves into two harmless components (carbon dioxide and water). This should dramatically improve the healing of the artery and will reduce the length of time a patient has to rely on blood thinning medication."

EUR1.2m Contract with Global Pharmaceutical Comp

RNS


RNS Number : 8146U

Venn Life Sciences Holdings PLC

21 October 2014








Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")



€1.2m Contract with Global Pharmaceutical Company



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the signing of a €1.2m agreement to conduct a Phase IV clinical trial with a Global Pharmaceutical Company specialising in allergic diseases.



The contract signing comes on the back of Venn completing the acquisition of Cardinal Systems in France, a CRO specialising in Data Management and Randomisation which enables Venn to offer the full service portfolio with in-house services. The addition of these services has been an instrumental factor in securing this contract. With over 25 years in the business, Venn has extensive experience in the management of paediatric trials. The study will be run in over 70 sites across Europe with the objective of recruiting 300 patients.



This now brings the total amount of new business won since May to €6.6m and demonstrates as a larger Group, Venn is able to win larger value pan-European multi-site contracts.



Speaking about the agreement, Venn CEO, Tony Richardson stated: "With the recent addition to our service portfolio and our geographic expansion throughout Europe, our clients are securely making the decision to choose us as their clinical trial partner for the future. I am particularly pleased that our first joint contract win with Cardinal is so significant and so soon after acquisition. I believe this represents an early endorsement of our decision to acquire data management and IRS capabilities and we are greatly encouraged by the pipeline for our new full service offering."

EUR1.4m contract win with US firm

RNS


RNS Number : 6509W

Venn Life Sciences Holdings PLC

11 November 2014








Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")



€1.4million contract with US firm for European Trial



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the signing of an agreement worth over €1.4 million to conduct a European wide Phase II study for a US based company.



The deal comes on the back of multiple significant contract signings for Venn this year and sees the Company expanding its US customer base. Including this contract, Venn has announced new business wins totaling €8m in the past six months. This volume of business represents a major step change for Venn and justifies the significant investment in personnel and infrastructure in the past 18 months.



Speaking about the agreement, Venn CEO, Tony Richardson stated: "The recent project wins demonstrate that our strategy of expanding our core services, our locations and our teams is coming to fruition for us as a company, and for our shareholders and our stakeholders. We now have a solid book of profitable contracts and a healthy pipeline of opportunities, which gives us confidence that we will deliver further growth in 2015."

Innovenn commences production at new facilities

RNS


RNS Number : 5065X

Venn Life Sciences Holdings PLC

20 November 2014










Venn Life Sciences Holdings Plc

("Venn" or the "Company")



Innovenn commences production of Labskin at new state of the art facilities



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that its innovation division, Innovenn, has commenced production of its pioneering product Labskin at their new state of the art laboratory facilities in the UK.



Labskin, a human skin equivalent, allows high quality skin research to be carried out in the sponsors own facilities. Unlike most skin models, Labskin provides an environment similar to human skin in that it can house microflora.



The commencement of production at these new facilities marks a milestone for Innovenn as they have sought to streamline operations to deal with larger order volumes and a wider geographic distribution. Innovenn have also recently recruited additional technical staff to assist with production and order fulfillment.



Tony Richardson, CEO of Venn Life Sciences commented: "We are delighted to be able to offer our clients one of the most exciting skin research products ahead of schedule from our facilities in York. We will continue to work and build capacity in order to increase our worldwide distribution of Labskin and the provision of associated microbiology services."

Year End Update

RNS


RNS Number : 5307A

Venn Life Sciences Holdings PLC

23 December 2014








Venn Life Sciences Holdings Plc

("Venn" or the "Company")



Year End Update



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces a strong close to 2014 with November seeing a record billing month in excess €900k and full year revenues are expected to be at least double the previous year's revenues (2013: €2.04m). The Company will provide further details of the year end performance in January.



This strong close has been driven by substantial contract wins since May this year exceeding €8m in total value and provides a firm foundation for 2015. The Company already has contracted revenue for next year in excess of €6m, as well outstanding proposals for new contracts worth a total of €18m.



With significant secured revenue for 2015 and the expectation that the Company will secure further contracts that will contribute to 2015, the Company is confident that it will deliver profitability and significant revenue growth next year.



Commenting on the Year End Update, CEO of Venn Life Sciences, Tony Richardson stated: "The strong close to the year driven by a number of new significant contracts has seen a major step change for Venn. We would like to reiterate that Venn has a solid book of profitable contracts and a healthy pipeline of opportunities giving us confidence for further growth and maiden profits next year."

Tipped in the New Year.

Up 5.93% today, not the 9% Moneyam is showing. Still good. Correction it is up 9% :-))

Contracts for EUR4.1m with US Biotech client
RNS
RNS Number : 7804I
Venn Life Sciences Holdings PLC
30 March 2015

30 March 2015

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")



Contracts worth EUR4.1m signed with US Biotech client



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces today the signing of new contracts worth over €4.1m with a leading US based Biotechnology client.



The deals are an extension of an existing contract which has doubled in size and the award of a new clinical trial to the value of €2.7m. These Phase II clinical trials, that evaluate the efficacy of a pioneering drug in the areas of Oncological hematology and Respiratory, will run over 24 months in multiple European and US sites. Venn has extensive experience in the management of Phase II trials with a history of over 25 years running studies throughout Europe.



Speaking about the agreement, Venn CEO, Tony Richardson stated: "The signing of these contracts is a compliment to all the team at Venn who have been diligently working with this client since last year. It reinforces our commitment to consistently deliver excellent international services and our ability to win larger projects from global clients. We are clearly seeing tangible results from our key investments over the course of 2014."

InnoVenn expands products and first sales in US
RNS
RNS Number : 2395J
Venn Life Sciences Holdings PLC
02 April 2015





Venn Life Sciences Holdings Plc

("Venn" or the "Company")



InnoVenn expands its Labskin product line and confirms first sales to the US



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that InnoVenn, the skin science division of Venn, has extended its product line and seen first sales in the US.



InnoVenn have introduced a new 12 well-plates version of the research grade human skin equivalent, Labskin. Labskin has traditionally been produced in 6 well-plate assays with unique qualities such as its ability to support microflora, improved barrier function and longer test window, positioning it as a world leader in the area of skin science research. The 6 well-plate provides a large area of skin for those requiring easy manipulation, application and sampling. It is ideally suited to large scale samples, repeated sampling and application protocols. In contrast the new 12 well-plates provide the same quality product but in a smaller format for study designs requiring additional technical and biological replicates. It allows Labskin to target a bigger market.



Labskin has established its utility in the cosmetic and dermatological skin research industries with key opinion leaders championing it as a viable alternative to testing products on human or animal skin. The European Union implemented a complete ban on animal testing for cosmetics in March 2013. This ban has led to the market seeking out viable and reliable alternatives for a host of different cosmetic and pharmaceutical products.



InnoVenn has also recently launched its United States service, shipping to a leading cosmetics, personal care and chemical testing group in Michigan who are carrying out tests to measure skin metabolism in different environments.



Commenting on this development Venn CEO, Tony Richardson stated: "This expansion of InnoVenn's product line illustrates that this part of the business is growing independently of the CRO business, which is our strategic plan, allowing InnoVenn to be well positioned to deliver on the full potential of its technology portfolio. Labskin continues to break barriers in terms of its capacity to replicate human skin and colonise microflora and we look forward to bringing Labskin to a global audience."

EUR 2m contract with leading European biotech
RNS
RNS Number : 8174P
Venn Life Sciences Holdings PLC
10 June 2015

10 June 2015

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")



Venn Signs €2m Contract with Leading European Biotech



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology, academic and medical device clients, announces today the signing of a €2m contract with a leading European Biotechnology company.



The Phase III study, in the area of Rheumatology, will cover multiple European countries, commences immediately and will run over 4 years with a high concentration of activity in year one. Venn has extensive experience in the management of Phase III trials with an excellent track record of multi-site and multi-cultural clinical trials. The contract win comes on the back of Venn reporting a 140% revenue increase in 2014 and €4.1m of new contracts in March of this year with a US based Biotechnology company.



Speaking about the agreement, Venn CEO, Tony Richardson stated: "The signing of this contract reinforces the continued success of our clinical and business development teams to win projects with leading international organisations. Venn has been steadily and continuously delivering on its strategy to win larger multi country scale contracts and to increase its footprint across Europe."

proactiveinvestors ,venn-life-sciences-riding-the-biotech-wave

Trading update
RNS
RNS Number : 8992V
Venn Life Sciences Holdings PLC
13 August 2015



Venn Life Sciences Holdings Plc

("Venn" the "Company" or the "Group")



Trading update



Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces a strong first half of 2015 with the Company billing in excess of €4m, up 170% against the same period in 2014 (H1: €1.5m).



The Company has demonstrated continued growth throughout 2015 driven by contract wins amounting to over €9m in the period to 30 June 2015.



Commenting on the figures, Venn CEO, Tony Richardson said: "Our fee income figures highlight the steady and consistent growth of the Company year on year with both repeat business and organic growth contributing to our excellent results and ability to win projects internationally. Our market continues to grow steadily and with a healthy pipeline of prospects we are well positioned to deliver further growth."



Venn will announce its interim results for the six months ended 30 June 2015 on the 22 September 2015.

10:25 02/11/2016
Director Deals - Venn Life Sciences Holdings PLC (VENN)
Allan Wood, Chairman, bought 230,000 shares in the company on the 31st October 2016 at a price of 21.67p. The Director now holds 230,000 shares. NOTE: Average price over 2 transactions. Story provided by StockMarketWire.com Director deals data provided by www.directorsholdings.com